"This fund offers a new way to tap into private market returns," said Sean O’Hara, president of Pacer ETF Distributors. "PEVC ...

The Gurugram-headquartered company, which is eyeing an initial public offering (IPO) and is in the planning stages, recently ...

Stock Market Highlights | US President Donald Trump waging a tariff war on Canada, Mexico and China sent a chill into global ...

Artificial-intelligence evangelists such as Sam Altman want to reshape the world, but they need mountains of money to do it. That is sparking a modern-day gold rush on Wall Street.

Saturdays budget clarifies asset sales tax for domestic investors, potentially reducing litigation. This and more in todays ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Private equity will have a more positive 2025 than it's had recent years, and institutional investors will likely turn their ...

The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth $279m.

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.

BloombergNEF says in a new report that global clean energy investment reached $2.1 trillion in 2024, more than doubling 2020 ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...